Astrazeneca plc - Articles - Page 16

Astrazeneca to withdraw diabetes drug Forxiga from Korea

Dec. 13, 2023

Astrazeneca Korea Co. Ltd. will pull its blockbuster diabetes drug, Forxiga (dapagliflozin), from the South Korean market, a company official confirmed to BioWorld, citing “multiple factors” like increasing local competition and continuing price cuts after patent expiry in 2023.

Developers’ RSV esprit draws Astrazeneca to $1.1B Icosavax buyout

Dec. 12, 2023

By Randy Osborne

Astrazeneca plc, which seemed to have backed away from vaccine development after the COVID-19 pandemic, clearly took a shine to Icosavax Inc.’s virus-like particle technology and signed a deal to take over the firm for as much as $1.1 billion.

South Korea anticipates drug pricing reform in 2024

Dec. 12, 2023

By Marian (YoonJee) Chu

As South Korea awaits potential changes to drug pricing policies for generics and novel ultra-expensive therapies like Novartis AG’s Kymriah (tisagenclecleucel), the domestic pharmaceutical industry is proactively voicing concerns about some policies that could do more harm than good.

Infection

Off-target immune response from modified mRNA impacts future development

Dec. 7, 2023

By Nuala Moran

The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it encodes has been found on some occasions to cause ribosomal frameshifting.

Bio-IT World Conference & Expo Europe

Is AI on the way to designing drugs? Astrazeneca thinks so

Dec. 1, 2023

By Shani Alexander

Artificial Intelligence (AI) driven tools have the ability to design new drugs, with a bit of help from humans, said Anders Hogner, from Astrazeneca plc’s R&D department at the Bio-IT World Conference & Expo Europe in London. “We don’t have anything out there yet,” he added, but the company appears to be working on it.

Bio-IT World Conference & Expo Europe

Is AI on the way to designing drugs? Astrazeneca thinks so

Nov. 30, 2023

By Shani Alexander

Artificial Intelligence (AI) driven tools have the ability to design new drugs, with a bit of help from humans, said Anders Hogner, from Astrazeneca plc’s R&D department at the Bio-IT World Conference & Expo Europe in London. “We don’t have anything out there yet,” he added, but the company appears to be working on it.

Biden to expand HHS authorities to address US drug shortages

Nov. 28, 2023

By Mari Serebrov

With drug shortages becoming a fact of life, U.S. President Joe Biden said he plans to issue a presidential determination to broaden the Department of Health and Human Services’ (HHS) authorities under the Defense Production Act to enable investment in the domestic manufacturing of essential medicines, medical countermeasures and other critical inputs that the president deems essential to the national defense.

Astrazenca launches Evinova digital health business

Nov. 21, 2023

By Shani Alexander

Astrazeneca plc launched a health-tech business aimed at bringing to market digital technological solutions that will optimize clinical trial design and delivery. The company, called Evinova, will offer solutions to reduce the time and cost of developing new drugs, bring care closer to patients at home and reduce the burden on health systems.

Astrazeneca’s AKT inhibitor is approved in breast cancer

Nov. 17, 2023

By Lee Landenberger

Along with Enhertu, Astrazeneca plc now has another breast cancer treatment in its portfolio and it may also become a blockbuster. Truqap (capivasertib), combined with the company’s Faslodex (fulvestrant), is now U.S. FDA-approved for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.

Immuno-oncology

AZD-6422, a novel dnTGFββRII-armored, CLDN18.2-targeted CAR T therapeutic

Nov. 16, 2023

CLDN18 is a cell surface membrane protein involved in the formation of tight junctions, and the expression of its CLDN18.2 isoform has been observed in pancreatic, gastric and esophageal tumors.